Abstract
Aims: Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of renal function in chronic kidney disease (CKD) up to one year. Whether this effect is maintained beyond 12. months and whether the magnitude of BP reduction affects estimated glomerular filtration rate (eGFR) is unknown. Methods and results: We examined eGFR in 46 CKD patients (baseline eGFR ≤60mL/min/1.73m2) on a yearly basis from 60months before to 3, 6, 12 and 24months after RDN. Ambulatory BP was measured before and after RDN. Linear mixed models analysis demonstrated a significant progressive decline in eGFR from months 60 to 12months (-15.47±1.98mL/min/1.73m2, P<0.0001) and from 12months to baseline prior to RDN (-3.41±1.64mL/min/1.73m2, P=0.038). Compared to baseline, RDN was associated with improved eGFR at 3months (+3.73±1.64mL/min/1.73m2, P=0.02) and no significant changes at 6 (+2.54±1.66mL/min/1.73m2, P=0.13), 12 (+1.78±1.64mL/min/1.73m2, P=0.28), and 24 (-0.24±2.24mL/min/1.73m2, P=0.91) months post procedure were observed. RDN significantly reduced daytime SBP from baseline to 24months post procedure (148±19 vs 136±17mmHg, P=0.03) for the entire cohort. Changes in SBP were unrelated to the eGFR changes at 6 (r=0.033, P=0.84), 12 (r=0.01, P=0.93) and 24months (r=-0.42, P=0.17) follow-up. Conclusion: RDN can slow further deterioration of renal function irrespective of BP lowering effects in CKD. RDN-induced inhibition of sympathetic outflow to the renal vascular bed may account for improved eGFR via alterations of intrarenal and glomerular hemodynamics.
| Original language | English |
|---|---|
| Pages (from-to) | 93-97 |
| Number of pages | 5 |
| Journal | International Journal of Cardiology |
| Volume | 232 |
| DOIs | |
| Publication status | Published - 1 Apr 2017 |
Keywords
- Blood pressure
- Chronic kidney disease
- Renal denervation
- Renal function
Research output
- 70 Citations
- 1 Article
-
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): A randomised, sham-controlled, proof-of-concept trial
Townsend, R. R., Mahfoud, F., Kandzari, D. E., Kario, K., Pocock, S. J., Weber, M. A., Ewen, S., Tsioufis, K., Tousoulis, D., Sharp, A. S. P., Watkinson, A. F., Schmieder, R. E., Schmid, A., Choi, J. W., East, C., Walton, A., Hopper, I., Cohen, D. L., Wilensky, R. & Lee, D. P. & 13 others, , 11 Nov 2017, In: The Lancet. 390, 10108, p. 2160-2170 11 p.Research output: Contribution to journal › Article › Research › peer-review
678 Link opens in a new tab Citations (Scopus)
Projects
- 1 Finished
-
Mechanisms and consequences of renal denervation in chronic kidney disease
Denton, K. (Primary Chief Investigator (PCI)), Broadhead, G. (Chief Investigator (CI)) & Schlaich, M. P. (Chief Investigator (CI))
NHMRC - National Health and Medical Research Council (Australia)
1/01/13 → 31/12/15
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver